Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVE1642 + sorafenib
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
AVE1642 + sorafenib is a combination of a **humanized monoclonal antibody (AVE1642) targeting type 1 insulin-like growth factor receptor (IGF-1R)** and **sorafenib**, a small-molecule multikinase inhibitor. AVE1642 blocks IGF-1R signaling, which is implicated in tumor cell growth and resistance to therapy. Sorafenib inhibits several receptor tyrosine kinases, including VEGFR, PDGFR, and RAF kinases, and is approved for the treatment of hepatocellular carcinoma and renal cell carcinoma. The combination has been investigated in early phase clinical trials for patients with advanced hepatocellular carcinoma and other solid tumors, aiming to explore safety, tolerability, pharmacokinetics, and preliminary efficacy. AVE1642 is administered intravenously, while sorafenib is given orally. Most patients experienced tumor stabilization, and no significant pharmacokinetic interactions or increased toxicities were observed when combining both agents[2].
- Brand names
- Nexavar
- Other names
- AVE1642 plus sorafenibAVE-1642 plus sorafenibAVE 1642 plus sorafenibAVE1642/sorafenib
02
Targets
PDGFR (PDGFR family)VEGFR (VEGFR family)RAF1 (c-Raf-1 (Y340D/Y341D))IGF-1R (Insulin-like growth factor 1 receptor)
Beyond the preview
Go deeper on AVE1642 + sorafenib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVE1642 + sorafenib.